| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Target: Z-form RNA/DNA structures (chemical probe). 2'-O-Methyl-8-methyl guanosine (m8Gm) is not a classical drug with a protein target; instead, it is a modified nucleoside that stabilizes non-canonical Z-form nucleic acid structures. It promotes and stabilizes Z-RNA and Z-DNA by favoring the syn conformation of the glycosidic bond, facilitating the alternating syn-anti backbone pattern characteristic of Z-form helices.
|
|---|---|
| ln Vitro |
In vitro, 2'-O-Methyl-8-methyl guanosine (m8Gm) stabilizes Z-RNA under low-salt conditions, enabling the study of Z-form nucleic acid structures. Oligonucleotides containing m8Gm exhibit increased Z-DNA stability in low-salt buffers (e.g., 10-50 mM NaCl), whereas natural nucleic acids require high salt concentrations (∼2 M NaCl) to adopt Z-form. No direct pharmacological activity (cell viability, enzyme inhibition) is reported.
|
| ln Vivo |
No in vivo studies have been performed with 2'-O-Methyl-8-methyl guanosine. This compound is not intended for in vivo administration for therapeutic purposes; it is a research tool for studying nucleic acid structure and function in cell-free systems. Its potential applications in vivo (e.g., as an antisense oligonucleotide modification) have not been explored.
|
| Enzyme Assay |
For cell-free Z-RNA stabilization assays: Z-RNA-forming oligonucleotides (e.g., repeating CG sequences, d(CG)n) are synthesized with m8Gm incorporated at specific positions. Oligonucleotides are dissolved in low-salt buffer (e.g., 10-50 mM NaCl, 5 mM Tris-HCl, pH 7.5) at 10-100 uM. CD (circular dichroism) spectroscopy is performed to monitor the transition from B-form (positive peak at ∼275 nm, negative peak at ∼210 nm) to Z-form (negative peak at ∼290 nm, positive peak at ∼210 nm) upon addition of the oligonucleotide to buffer. UV absorbance at 254 nm and 295 nm can also measure Z-form stability.
|
| Cell Assay |
No cell-based assays are performed with this compound, as it is a nucleoside used for chemical synthesis of modified oligonucleotides, not a compound that is directly added to cells for biological activity studies. Modified oligonucleotides containing m8Gm may be transfected into cells for gene regulation studies, but the nucleoside itself is not used in cell culture. No specific cell-based protocols have been reported.
|
| Animal Protocol |
No animal studies are conducted with 2'-O-Methyl-8-methyl guanosine. The compound is not administered to animals. It is used exclusively as a building block for the synthesis of modified oligonucleotides for in vitro structural studies or as a research reagent in nucleic acid chemistry. No in vivo efficacy or safety studies have been performed.
|
| ADME/Pharmacokinetics |
PK properties are not applicable for this compound, as it is not intended for in vivo administration as a drug. As a modified nucleoside (MW 311.29), if administered systemically, it would likely be rapidly metabolized by nucleoside phosphorylases or incorporated into nucleic acids, but no PK studies have been performed. The compound is for research use only and is not a drug candidate.
|
| Toxicity/Toxicokinetics |
No toxicity data are available for this compound. As a modified nucleoside, it is not cytotoxic at concentrations used in oligonucleotide synthesis. The compound is for research use only and is not intended for human therapeutic administration. It is considered non-hazardous for transport under normal laboratory conditions. Not for human consumption.
|
| References |
|
| Additional Infomation |
2'-O-Methyl-8-methyl guanosine is a research reagent, not a drug. It is not FDA-approved for clinical use. It is used in nucleic acid chemistry and structural biology to study Z-form DNA and RNA conformations. It is also used to increase the stability of oligonucleotides for potential antisense or siRNA applications, and as a tool for investigating the biological roles of Z-nucleic acids in gene regulation, inflammation, and immunity.
|
| Molecular Formula |
C12H17N5O5
|
|---|---|
| Molecular Weight |
311.293882131577
|
| Exact Mass |
311.122
|
| CAS # |
2306782-64-7
|
| PubChem CID |
137249367
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
489
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1[C@H](CO)[C@H]([C@H]([C@@H]1N1C(C)=NC2C(NC(=N)N=C12)=O)OC)O
|
| InChi Key |
VKBDRYNPOJCCAX-IOSLPCCCSA-N
|
| InChi Code |
InChI=1S/C12H17N5O5/c1-4-14-6-9(15-12(13)16-10(6)20)17(4)11-8(21-2)7(19)5(3-18)22-11/h5,7-8,11,18-19H,3H2,1-2H3,(H3,13,15,16,20)/t5-,7-,8-,11-/m1/s1
|
| Chemical Name |
2-amino-9-[(2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-8-methyl-1H-purin-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2124 mL | 16.0622 mL | 32.1244 mL | |
| 5 mM | 0.6425 mL | 3.2124 mL | 6.4249 mL | |
| 10 mM | 0.3212 mL | 1.6062 mL | 3.2124 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
